How Does the Asthmatic Patient Arrive at the Emergency Department? Data from the SABINA EMERGENCIAS Multicenter Study
Article Sidebar
Main Article Content
Abstract
Introduction: The objectives of asthma control are to prevent the onset of symptoms and reduce the risk of exacerbations and mortality through medical education, inhaler technique, adherence to controller medication and indication of action plans (AP); but patients experience exacerbations of varying severity. The main objective of the SABINA EMERGENCIAS study was to describe how patients attend the emergency department (ED), considering the frequency and use of rescue medication. Secondary objectives: ED visits; use of systemic corticosteroids (SC), short-acting beta-2 agonists (SABA) and controller therapy; availability of AP.
Methods: Cross-sectional, observational, descriptive study in 4 hospitals in the metropolitan area of Buenos Aires in adults with asthma.
Results: n=323 (age:43.7±16.8 years; women:66.6%): 61.3% were not followed by specialists; 90.1% used SABA as rescue medication (median:10 puffs; range 0-100) the previous week; 75.9% had ≥1 visit to the ES the previous year (median: 2 [0-100]); 29.4% had been hospitalized; 59.1% received ≥1 cycle of CS; median SABA consumption: 3 cannisters/year (0-23); 51.7% had used ≥3 cannisters; 30% did not use maintenance therapy (23% used SABA); 75.9% did not perform regular maintenance therapy; 77.1% did not have an AP.
Conclusion: A small proportion of asthmatic patients attending the ES are followed by specialist physicians, with high consumption and high frequency of SABA application as rescue medication and low adherence to maintenance treatment. The need to optimize management is highlighted, with emphasis on referral to specialists, adherence to treatment and prescription of APs.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Ministerio de Salud de la Nación. Protocolo de Orientación Para El Diagnóstico y Manejo Del Asma En Adultos. 2016. [Internet]. [Consultado 12 abr 2024]. Disponible en: https://iah.salud.gob.ar/doc/Documento166.pdf
Arias SJ, Neffen H, Bossio JC et al. Prevalencia y características clínicas del asma en adultos jóvenes en zonas urbanas de Argentina. Arch Bronconeumol 2018;54(3):134–139. Doi: 10.1016/j.arbres.2017.08.021.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, Updated 2023. [Internet]. [Consultado 12 abr 2024]. Disponible en:https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Full-report-23_07_06-WMS.pdf
Bourdin A, Bjermer L, Brightling C et al. ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. Eur Respir J 2019;54(3):1900900. Doi: 10.1183/13993003.00900-2019.
Stanford RH, Shah MB, D’Souza AO et al. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol 2012;109(6):403–407. Doi: 10.1016/j.anai.2012.08.014.
Suissa S, Ernst P, Boivin JF et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149(3 Pt 1):604–610. Doi: 10.1164/ajrccm.149.3.8118625.
van der Valk RJP, Baraldi E, Stern G et al. Daily exhaled nitric oxide measurements and asthma exacerbations in children. Allergy 2012;67(2):265–271. Doi: 10.1111/j.1398-9995.2011.02734.x.
Mattarucco W, Altieri H BR. Patrón de prescripción de agonistas beta-2 de acción corta y potenciales efectos sobre el control del asma: cohorte argentina del estudio SABINA III. Rev Arg Med 2022;10(2):116–123.
Castiglioni N, Ledesma F, Zuccarino N et al. Consumo de beta-2 agonistas de acción corta en farmacias de la Ciudad de Córdoba (Pharmacy Survey). Rev Farm 2022;164(2):31–36.
Chirino G, del Olmo R, Castaño G. El asma no controlada en la atención primaria: implementación y uso práctico de ReferID. Respirar 2023;15(2); 81-87. Doi: 10.55720/respirar.15.2.1.
Maillo M, Valdez P, Camargo G et al. Manejo de la crisis asmática en el adulto. Rev Arg Med 2022;10((Supl. 1)):S36–S43.
Most JF, Ambrose CS, Chung Y et al. Real-World Assessment of Asthma Specialist Visits Among U.S. Patients with Severe Asthma. J Allergy Clin Immunol Pract 2021;9(10):3662-3671.e1. Doi: 10.1016/j.jaip.2021.05.003.
Lenhardt RO, Catrambone CD, Walter J et al. The asthma emergency department visit: treating a crisis in the midst of uncontrolled disease. Ann Allergy Asthma Immunol 2008;100(3):237–243. Doi: 10.1016/S1081-1206(10)60448-6.
Nannini LJ, Luhning S, Rojas RA et al. Position statement: asthma in Latin America. IS short-acting beta-2 agonist helping or compromising asthma management? J Asthma 2021;58(8):991–994. Doi: 10.1080/02770903.2020.1777563.
Maspero JF, Jardim JR, Aranda A et al. Insights, attitudes, and perceptions about asthma and its treatment: findings from a multinational survey of patients from Latin America. World Allergy Organ J 2013;6(1):19. Doi: 10.1186/1939-4551-6-19.
Neffen H, Fritscher C, Schacht FC et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica 2005;17(3):191–197. Doi: 10.1590/s1020-49892005000300007.
George M, Bender B. New insights to improve treatment adherence in asthma and COPD. Patient Prefer Adherence 2019;13:1325–1334. Doi: 10.2147/PPA.S209532.
Williams LK, Peterson EL, Wells K et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011;128(6):1185-1191.e2. Doi: 10.1016/j.jaci.2011.09.011.
Gillisen A. Patient’s adherence in asthma. J Physiol Pharmacol 2007;58 Suppl 5(Pt 1):205–222.
Sívori M, Pascansky D. Costos directos en asma aguda hospitalizada en un hospital público de la Ciudad de Buenos Aires. Rev Am Med Resp 2020;20(2):132–140.
Goronfolah L, Abulaban A, Barnawi AI et al. The Effectiveness of Written Asthma Action Plan at the National Guard Health Affairs’ Asthma Clinic. Cureus 2019;11(11):e6247. Doi: 10.7759/cureus.6247.